Biotechnology

AIM ImmunoTech

Tencent

Financial Analysis

00700

AIMID

GOOG

GOOGL

NNOX

000656

TCTZF

TCEHY

80700

GGLS

GGLL

NANO

HTCD

SBCWW

<p>After the Hong Kong stock market closed on November 13, Beijing time, <span class="security-tag" type="security-tag" counter_id="ST/HK/700" name="TENCENT" trend="">$TENCENT(00700.HK)</span> released its third-quarter 2025 results. Overall, while there were not many surprises compared to expectations, stability remains the key theme, with no significant weaknesses in the three major business lines. Since the beginning of this year, Tencent has entered a new investment cycle, yet traces of the management's refined operations and effective capital allocation can still be observed. Specifically: 1. Gaming remains the standout: Tencent Games maintained high growth of 23% in the third quarter, driven by the product cycle. Overseas, under the leadership of Supercell's 'Clash Royale,' it continued to surge (with favorable exchange rate contributions)...</p>

TENCENT

Meta Platforms

AIM IMMUNOTECH INC

Alphabet - C

Alphabet

Nano-X Imaging

JINKE PROPERTY

SBC Medical

Tencent Holdings Limited

TENCENT-R

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

Pro Ultra 7-10Yrs

Nanoco Group PLC

Tencent HK SDR 10to1

SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM)

Tencent: Not playing heartbeats with Meta, just seeking stable happiness

AIM ImmunoTech released FY2025 Q4 earnings on March 27 (EST), actual revenue USD 21K (forecast USD 0), actual EPS USD -1.4473 (forecast USD -0.939)

AIM ImmunoTech released FY2025 earnings on March 27 (EST), actual revenue USD 88 K (forecast USD 100 K), actual EPS USD -8.6234 (forecast USD -7.7422)

AIM ImmunoTech Inc Obtains Cancer Therapy Patent and Plans to Apply for Orphan Drug Status in Japan

AIM ImmunoTech Signs Agreement for Ampligen's Phase 3 Clinical Trial

AIM ImmunoTech Reports Q3 2025 Earnings and Pancreatic Cancer Project Progress

AIM ImmunoTech released FY2025 Q3 earnings on November 17 (EST), actual revenue USD 26K (forecast USD 0), actual EPS USD -1.5671 (forecast USD -0.975)

AIM ImmunoTech released FY2025 9 Months Earnings on November 17, 2025 (EST), with actual revenue of USD 67K and EPS of USD -10.5059

AIM ImmunoTech Delays Submission of Third Quarter Financial Report

AIM ImmunoTech Presents Phase II Clinical Trial Data for Ampligen in Treating Ovarian Cancer

AIM ImmunoTech Submits Revised Articles of Incorporation

Analyst Woo Covers Healthcare Sector Stocks

AIM Expands International Market Protection Through Patent Strategy and Seeks Cooperation and Revenue Growth

AIM ImmunoTech to Present Pancreatic Cancer Clinical Project Data at Marie Curie Congress

AIM ImmunoTech Reports Q2 2025 Financials with Increased Net Loss

AIM ImmunoTech released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 41K, actual EPS USD -8.8826

AIM ImmunoTech released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 25K (forecast USD 100K), actual EPS USD -3.676 (forecast USD -8)

AIM ImmunoTech Presents Ampligen Clinical Data at Annual Conference

AIM ImmunoTech's AMPLIGEN and IMFINZI Show Promising Results in Pancreatic Cancer

AIM ImmunoTech Patents Related to Ampligen

AIM ImmunoTech Inc. Launches $8 Million Public Offering

Allbirds

Allied Gaming & ENT

Immutep

Hub Cyber Security

EUREKA ACQUISITION CORP COM USD0.0001 A (SUBS/RTS 03/07/2026)

Propanc Biopharma

Xanadu Quantum Tech - B

Ascent Solar Tech

VisionSys AI

K-Tech Solutions

Kiniksa Pharmaceuticals

MiMedx

Rigel Pharma

CapForce Inc.

Vertex Pharma

Regeneron Pharma

Argenx

Alnylam Pharma

Beigene

Natera

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

AIM ImmunoTech(AIM.US)

AIM ImmunoTech Stock Performance Chart